Precision medicine
data modalities we can help you with
The precision medicine data modalities Sonrai can help you with span genomic, proteomic, imaging, and clinical datasets - all integrated inside a secure, reproducible environment to generate decision-ready evidence for drug development programmes.
Supporting discovery, translational and clinical programmes across precision medicine.
Any pipeline.
On demand.
Sonrai supports the full NF-core library on demand - if your analysis requires a pipeline we have not run before, we scope and deploy it. Pipelines are driven by what your programme needs, not a fixed catalogue.
Every pipeline runs inside a governed Trusted Research Environment. Outputs are versioned, traceable and reproducible - so the evidence your programme generates is defensible from day one.
Identify variants and genetic drivers of disease and treatment response
Whole genome and exome sequencing data reveals the genetic architecture underlying disease biology. Sonrai integrates variant data with transcriptomic and clinical evidence to identify high-confidence drivers and support target selection decisions.
- WGS (whole genome sequencing)
- WES (whole exome sequencing)
- Variant calling and annotation
Most relevant to Target ID and Validation · Patient Stratification
All outputs versioned and reproducible inside Sonrai Discovery.
Germline variants associated with CD8+ T cell infiltration - GWAS analysis across TCGA tumours
Precision Patient Stratification
WGS and digital pathology integrated with clinical trial outcomes to identify patient subgroups with distinct response profiles - enabling clearer trial design and patient selection strategy.
View case studyDiscover biomarkers, mechanisms and patient subgroups from expression data
Transcriptomic data reveals what genes are actually doing across tissues, cell types and patient cohorts. Sonrai integrates bulk, single-cell and spatial expression data with clinical and imaging evidence to identify the biological signals that drive treatment response.
- Bulk RNA-seq
- Single-cell RNA-seq
- Spatial transcriptomics
Most relevant to Translational Analysis · Target ID and Validation
All outputs versioned and reproducible inside Sonrai Discovery.
Gene expression heatmap - responder vs non-responder cohort analysis
Immunotherapy Development - From Bench to Bedside
Single-cell and bulk RNA-seq analysis used across preclinical and clinical stages to identify immune cell population changes and prognostic biomarkers of response.
View case studyUnderstand gene regulation and epigenetic drivers of disease
Epigenomic data captures the regulatory landscape that controls gene expression without changing the underlying sequence. Sonrai integrates methylation data with genomic and transcriptomic evidence to identify epigenetic biomarkers and regulatory mechanisms relevant to your programme.
- DNA methylation (bisulfite sequencing)
- WGBS / RRBS
Most relevant to Translational Analysis · Target ID and Validation
All outputs versioned and reproducible inside Sonrai Discovery.
Chromatin signatures of treatment response - open chromatin, H3K4me1 and H3K27ac tracks across patient groups
Multi-Modal Biomarker Discovery
Methylation data integrated with RNA-seq, proteomics, and imaging evidence to identify epigenetic biomarker signatures in early-stage oncology diagnostics.
View case studyValidate biomarker signals and connect protein expression to clinical outcomes
Proteomic data captures what the genome is actually doing at the protein level. Sonrai integrates processed proteomic datasets with genomic and clinical evidence to validate biomarker hypotheses and build the multi-omic case for treatment response.
- Olink proteomics
- Mass spectrometry (via nf-core/quantms)
Most relevant to Translational Analysis · Target ID and Validation
All outputs versioned and reproducible inside Sonrai Discovery.
Protein biomarker signals - expression across patient cohorts
Multi-Omic Strategy for Optimising Oncology Clinical Trial Success
Olink proteomics integrated with clinical outcomes using MOFA to identify multi-omic biomarkers linked to survival in a Phase II NSCLC trial.
View case studyCharacterise immune cell populations and dynamics from cytometry data
Cytometry data profiles immune cell populations and their behaviour in response to treatment. Sonrai integrates processed cytometry datasets with molecular and clinical evidence to support mechanism of action studies, responder analysis and immune profiling.
- Flow cytometry
- CyTOF (processed datasets)
Most relevant to Translational Analysis · Patient Stratification
All outputs versioned and reproducible inside Sonrai Discovery.
Immune cell dynamics - responder vs non-responder population analysis
Multi-Omic Strategy for Optimising Oncology Clinical Trial Success
Flow cytometry and CyTOF data integrated with Olink proteomics and clinical outcomes using MOFA to distinguish high responder groups in a Phase II clinical trial.
View case studyIdentify patient subgroups and prognostic signals from tissue data
Imaging data adds spatial and phenotypic context that molecular data alone cannot provide. Sonrai integrates digital pathology and whole slide imaging with omics and clinical datasets to surface biologically meaningful patterns - and support patient selection and stratification decisions.
- H&E
- IHC
- Whole slide imaging
Most relevant to Translational Analysis · Patient Stratification
All outputs versioned and reproducible inside Sonrai Discovery.
Spatial and molecular signals - integrated tissue analysis
Integrating Imaging and Omic Data
RNA-seq, IHC, and H&E imaging integrated with proteomic and clinical data to identify novel patient subgroups and support drug target discovery in oncology.
View case studyBuild the evidence base for trial design and patient selection
Clinical datasets are what connect biological findings to the decisions your programme needs to make. Sonrai integrates trial data, survival endpoints and response assessments with molecular and imaging evidence to generate the stratification and biomarker outputs teams need to move forward with confidence.
- Clinical trial datasets
- Survival and outcomes data
- RECIST data
Most relevant to Patient Stratification · Translational Analysis
All outputs versioned and reproducible inside Sonrai Discovery.
Overall survival by treatment arm - patient stratification evidence
Precision Patient Stratification
WGS and digital pathology integrated with clinical trial outcomes to identify patient subgroups with distinct response profiles - enabling clearer trial design and patient selection strategy.
View case studyWorking with something
not listed here?
Many programmes involve data combinations that don't fit neatly into a single category. Talk to our team about your specific dataset and we will outline how we would approach it.
All analyses are performed within a secure Trusted Research Environment - protected, governed, and fully reproducible.